A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

DonanemabOngoingActive not recruitingPhase 3Open NCT04437511 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

NCT04437511 · Trial Tracker · ComplyRx